Infact, ranibizumab should be atleast 2.5 times more efficacious than bevacizumab for it to be cost-effective.[ 7 ] The cost difference between ranibizumab and bevacizumab could be highly significant for people who have limited or no health insurance coverage and this aspect assumes a greater significance in the Indian scenario.
← all excerpts
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration.
1
—
—